Unknown

Dataset Information

0

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.


ABSTRACT:

Background

Patients with stage IV lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs). Whether treatment with TKI improves outcomes in patients with resected lung adenocarcinoma and EGFR mutation is unknown.

Methods

Data were analyzed from a surgical database of patients with resected lung adenocarcinoma harboring EGFR exon 19 or 21 mutations. In a multivariate analysis, we evaluated the impact of treatment with adjuvant TKI.

Results

The cohort consists of 167 patients with completely resected stages I to III lung adenocarcinoma. Ninety-three patients (56%) had exon 19 del, 74 patients (44%) had exon 21 mutations, and 56 patients (33%) received perioperative TKI. In a multivariate analysis controlling for sex, stage, type of surgery, and adjuvant platinum chemotherapy, the 2-year disease-free survival (DFS) was 89% for patients treated with adjuvant TKI compared with 72% in control group (hazard ratio = 0.53; 95% confidence interval: 0.28-1.03; p = 0.06). The 2-year overall survival was 96% with adjuvant EGFR TKI and 90% in the group that did not receive TKI (hazard ratio: 0.62; 95% confidence interval: 0.26-1.51; p = 0.296).

Conclusions

Compared with patients who did not receive adjuvant TKI, we observed a trend toward improvement in DFS among individuals with resected stages I to III lung adenocarcinomas harboring mutations in EGFR exon 19 or 21 who received these agents as adjuvant therapy. Based on these data, 320 patients are needed for a randomized trial to prospectively validate this DFS benefit.

SUBMITTER: Janjigian YY 

PROVIDER: S-EPMC3778680 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.

Janjigian Yelena Y YY   Park Bernard J BJ   Zakowski Maureen F MF   Ladanyi Marc M   Pao William W   D'Angelo Sandra P SP   Kris Mark G MG   Shen Ronglai R   Zheng Junting J   Azzoli Christopher G CG  

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110301 3


<h4>Background</h4>Patients with stage IV lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs). Whether treatment with TKI improves outcomes in patients with resected lung adenocarcinoma and EGFR mutation is unknown.<h4>Methods</h4>Data were analyzed from a surgical database of patients with resected lung adenocarcinoma harboring EGFR exon 19 or 21 mutations. In a multivariate analysis, we eval  ...[more]

Similar Datasets

| S-EPMC8674600 | biostudies-literature
| S-EPMC545207 | biostudies-literature
| S-EPMC3186869 | biostudies-literature
| S-EPMC549606 | biostudies-literature
| S-EPMC5123695 | biostudies-literature
| S-EPMC4364680 | biostudies-literature
| S-EPMC2409244 | biostudies-literature
| S-EPMC5344291 | biostudies-literature
| S-EPMC5842518 | biostudies-literature
| S-EPMC3922700 | biostudies-literature